A
001540
vs
NOVN
A
001540
NOVN
Over the past 12 months, Ahn-Gook Pharmaceutical Co Ltd has underperformed NOVN, delivering a return of +24% compared to the NOVN's +32% growth.
This Feature is Available on
Paid Plans
Paid Plans
This Feature is Available on Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
14-day money-back guarantee
Smart Verdict
AI-Powered
Not Sure Which Stock Wins?
Let AI Decide.
Let AI Decide.
001540
NOVN
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Summarizing...
We need a little more time to summarize the results
Valuation Comparison
A
Intrinsic Value
17 581.51
KRW
Undervaluation 54%
NOVN
Intrinsic Value
107.11
CHF
Overvaluation 18%
| Company | Last Price | Intrinsic Value | DCF Value | Relative Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
A
|
Ahn-Gook Pharmaceutical Co Ltd
KOSDAQ:001540
|
8 070
KRW
|
|||||
|
Novartis AG
SIX:NOVN
|
130.16
CHF
|
|||||
No Stocks Selected
Compare the stock's valuation with its competitors.
Valuation Scenario:
Growth Comparison
Growth Over Time
001540, NOVN
001540, NOVN
Revenue
www.alphaspread.com
No Stocks Selected
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
A
|
Ahn-Gook Pharmaceutical Co Ltd
Revenue
|
|||||||||||
|
|
Novartis AG
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
No Stocks Selected
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
001540, NOVN
001540, NOVN
Free Cash Flow
www.alphaspread.com
No Stocks Selected
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
A
|
Ahn-Gook Pharmaceutical Co Ltd
KOSDAQ:001540
|
|||||||||
|
|
Novartis AG
SIX:NOVN
|
|||||||||
No Stocks Selected
Compare company's free cash flow with its competitors.
Gross Margin
Ahn-Gook Pharmaceutical Co Ltd
64.7%
NOVN
75.8%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
A
|
Ahn-Gook Pharmaceutical Co Ltd | ||||
|
|
Novartis AG | ||||
Operating Margin
Ahn-Gook Pharmaceutical Co Ltd
5.6%
NOVN
33.2%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
A
|
Ahn-Gook Pharmaceutical Co Ltd | ||||
|
|
Novartis AG | ||||
Net Margin
Ahn-Gook Pharmaceutical Co Ltd
3.3%
NOVN
24.8%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
A
|
Ahn-Gook Pharmaceutical Co Ltd | ||||
|
|
Novartis AG | ||||
FCF Margin
Ahn-Gook Pharmaceutical Co Ltd
12.4%
NOVN
27.1%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
A
|
Ahn-Gook Pharmaceutical Co Ltd | ||||
|
|
Novartis AG | ||||
ROE
Ahn-Gook Pharmaceutical Co Ltd
5.9%
NOVN
31%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
A
|
Ahn-Gook Pharmaceutical Co Ltd | ||||
|
|
Novartis AG | ||||
ROA
Ahn-Gook Pharmaceutical Co Ltd
3.3%
NOVN
13.1%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
A
|
Ahn-Gook Pharmaceutical Co Ltd | ||||
|
|
Novartis AG | ||||
ROIC
Ahn-Gook Pharmaceutical Co Ltd
5.4%
NOVN
17.8%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
A
|
Ahn-Gook Pharmaceutical Co Ltd | ||||
|
|
Novartis AG | ||||
ROCE
Ahn-Gook Pharmaceutical Co Ltd
7.4%
NOVN
23.8%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
A
|
Ahn-Gook Pharmaceutical Co Ltd | ||||
|
|
Novartis AG | ||||
Solvency Comparison
A
Ahn-Gook Pharmaceutical Co Ltd
Equity Waterfall
Assets
Liabilities
Equity
No Stocks Selected
Compare company's equity waterfall with its competitors.
Balance Sheet Comparison
Stocks Performance
Stocks Performance
001540, NOVN
001540, NOVN
Performance Gap
001540, NOVN
001540, NOVN
Performance By Year
001540, NOVN
001540, NOVN
Loading
No Stocks Selected
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Compare 001540 to other stocks
LLY
Eli Lilly and Co
More expensive
vs Ahn-Gook Pharmaceutical Co Ltd
JNJ
Johnson & Johnson
More expensive
vs Ahn-Gook Pharmaceutical Co Ltd
ROG
Roche Holding AG
More expensive
vs Ahn-Gook Pharmaceutical Co Ltd
AZN
AstraZeneca PLC
More expensive
vs Ahn-Gook Pharmaceutical Co Ltd
Select Stock to Compare
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Loading...
Unlock Full Access to Alpha Spread
Create Free Account
